Share This Article
The "Drone Era" Is Here – and Every Electric UAV Needs This Company's Invention
If you want tangible proof that the “Drone Era” is here, just look at the daily news feeds.
How would you like to put an extra $125,000 in your nest egg? You can potentially do it this year - and you'll only have to risk $20 to learn how. Click here.
Email this Article
September 27, 2016
Here are the key differences between Hillary Clinton and Donald Trump on taxes.
September 23, 2016
This was the very first stock we recommended on the very first day Private Briefing was published – Aug. 11, 2011.
On that day, you could've owned it for less than nine bucks a share – $8.60.
That's a distant memory.
We've re-recommended these shares more than a dozen times since then, so successive "classes" of our readers can participate in these gains.
And sure enough, this stock hit an all-time high at midday yesterday… up a whopping 717% from that first day we wrote about it.
September 21, 2016
The first presidential debate is upon us and the top issue on voters' minds: the state of our current tax code.
July 6, 2016
Big-cap investors were profoundly underwhelmed when the Obama administration caused Pfizer Inc. to cancel a $150 billion buyout of another massive pharma, Allergan Plc.
Like most deal-making at this level, there was a lot at stake. Allergan has a portfolio packed with name-brand drugs with long patent lives and a robust generics business. What's more, the deal would have allowed Pfizer to relocate its headquarters to the (extremely) tax-friendly Republic of Ireland and save a ton on payments to Uncle Sam.
Now, normally when a deal like this falls through, the shares take a serious pounding, but the smart money is holding its nerve. In fact, the stock is up just over 10% year to date. That says a lot.
Those investors, along with folks who buy in right now, stand to be richly rewarded in the future.
January 12, 2016
It’s important that you don’t give in to the recent stock market sell-off – that’s what Wall Street wants. We’re here to build wealth no matter what the markets throw our way.
So here’s a look at what you’re not hearing at the moment – including why the market sell-off could be a monster buying opportunity!
November 23, 2015
Pfizer Inc. (NYSE: PFE) and competitor Allergan Plc. (NYSE: AGN) announced the largest healthcare deal in history today (Monday).
The combination is a very bullish catalyst for the PFE stock price.
November 20, 2015
The Pfizer stock price is up 0.5% today as the U.S. drug giant remains in advanced stages to buy Allergan Plc. (NYSE: AGN).
Pfizer Inc. (NYSE: PFE) is pushing forward with the deal despite the best wishes of the U.S. Treasury, which is trying to curb such mergers.
July 28, 2015
7/28/15 PFE: Shares of Pfizer Inc. (NYSE: PFE) gained more than 1% after it reported stronger than expected adjusted quarterly profits. But the bigger news was the firm's 7% decline in its quarterly revenue figures. The company's global profits were affected by a strong U.S. dollar.
The Pfizer earnings and Merck earnings reports were both released this morning (Tuesday), and investors are acting differently to these major pharmaceutical stocks.
Pfizer Inc. (NYSE: PFE) stock was up 1.3% in early trading despite missing earnings per share estimates. Merck shares were down 2% despite topping estimates.
May 21, 2015
5/21/2015: Pharmaceutical giant Pfizer Inc. (NYSE: PFE) is in focus after it received a heap of praise from one of Wall Street's most prominent banks, Jefferies. The firm said Pfizer is its top global pharmaceutical stock to own. PFE made our list of most profitable pharmaceutical companies this year, with pharma revenue near $45 billion […]
May 14, 2015
5/14/2015: Pfizer Inc. (NYSE: PFE) made our list of most profitable pharmaceutical companies this year, with pharma revenue near $45 billion annually. Pfizer’s diabetes treatment Lyrica is the company’s biggest revenue generator as it brought in $5.1 billion in 2014. The pharmaceutical industry is one of the most profitable sectors in the world. More than […]
April 3, 2015
4/3/15: Pfizer Inc. (NYSE: PFE) is ceasing vaccine sales operations in China after the Chinese government failed to renew an import license for one of its products, a move that the company said will cause a shortage of the treatment in China. The vaccine protects toddlers against pneumococcal disease that can lead to pneumonia and […]
March 27, 2015
Pfizer Inc. (NYSE: PFE) has seen its earnings and revenue plummet during the last several years thanks to generic drugmakers invading the market with their lower priced alternatives and a number of large acquisitions over the past few years. Drugs that are currently in phase 3 trials should provide a kick to PFE earnings. Pfizer […]
March 20, 2015
3/19/15: Pfizer Inc. (NYSE: PFE) announced that the results from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), conducted to evaluate its best-selling vaccine Prevenar 13, have been published in the March issue of the New England Journal of Medicine. Pfizer announced that the vaccine met both primary and secondary endpoints specified for the study […]
February 5, 2015
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced plans to purchase Hospira, Inc. (NYSE: HSP) in a deal worth $17 billion, or $90 per share. The acquisition will give Pfizer access to Hospira's bio-similars (officially approved subsequent versions of innovative drugs). The $90 per-share offer is a 39% premium to the target's stock at the close […]
January 28, 2015
Yesterday was a rough day for earnings reports. Shares of Pfizer Inc. (NYSE: PFE) slipped 0.6% today on news the company slashed its 2015 guidance during its lackluster earnings report. E.I. DuPont De Nemours and Co. (NYSE: DD) slipped 1.25% after the company offered a weak 2015 outlook and took a hit on earnings thanks to a stronger dollar. Bristol-Myers Squibb Co. (NYSE:BMY) […]
November 17, 2014
The S&P 500 eked out a 1.5-point gain Monday to strike yet another record high as a fresh round of mergers and acquisitions fueled optimism in the markets.
Striking a Deal: Healthcare giant Pfizer Inc. (NYSE: PFE) announced a plan to manufacture cancer drugs with German rival Merck & Co. Inc. (NYSE: MRK). According to terms of the deal, Pfizer will pay an upfront fee to Merck worth $850 million. The deal could see Merck earn another $2 billion as the companies' efforts […]
October 28, 2014
Shares of Pfizer Inc. (NYSE: PFE) were up more than 1% this morning on news that the company bested third-quarter earnings expectations. The pharmaceutical giant reported per-share earnings of $0.42, beating analyst estimates by $0.03. The company cited growth in sales of its cancer treatments and cited increased demand in emerging markets. However, the company […]
September 24, 2014
The Wall Street Journal reports that Pfizer Plc (NYSE: PFE) had approached Irish drug maker Actavis Plc (NYSE: ACT) recently about a proposed takeover that would have allowed the U.S. firm to re-domicile in Europe and lower its tax bill. However, the talks have broken down. Given the new rules revealed this week by the U.S. Department of Treasury, any inversions moving forward […]
August 11, 2014
Pfizer stock (NYSE: PFE) will soon feel the pressure from the wave of lawsuits being filed claiming that Pfizer's blockbuster drug Lipitor – the world's best-selling drug of all time – causes type-2 diabetes in women. With a market cap of more than $180 billion, the world's largest pharmaceutical firm's pockets run deep. Lipitor alone brought in […]
August 8, 2014
Updated August 14, 2014: Pfizer stock (NYSE: PFE) will soon feel the pressure from the wave of lawsuits being filed claiming that Pfizer's blockbuster drug Lipitor – the world's best-selling drug of all time – causes type-2 diabetes in women.
"This will be a huge overhang on Pfizer stock," Money Morning Capital Wave Strategist Shah Gilani said. "Investors have to watch developments closely."
With a market cap of more than $180 billion, the world's largest pharmaceutical firm's pockets run deep. Lipitor alone brought in global sales of more than $125 billion for Pfizer over the 14-and-a-half years since its 1996 market debut (Pfizer's patent on Lipitor expired on November 30, 2011). More than 29 million patients took the drug just in the United States.
Shares of pharmaceutical giant Pfizer Inc. (NYSE: PFE) are on the decline in pre-market hours on news that the company is confronting a wave of lawsuits from women over possible side effects from its anti-cholesterol drug Lipitor. According to multiple reports, the the drug may give women type-2 diabetes at a rate of 5.6 per […]
June 18, 2014
Today's hot stocks: While the FOMC meeting took center stage on Wall Street today, a number of stocks moved on earnings, company developments, and analysts' actions.
Featured on Wednesday's hot stocks to watch list is an economic bellwether hitting an all-time high, a biopharmaceutical company surging on a promising treatment for lung infections, and a biopharma skyrocketing in its IPO.
June 12, 2014
The American Society of Clinical Oncology meets every spring. It's attended by some 30,000 people and hosts 4,000 presentations.
Investors like us love ASCO because of the so-called "ASCO Effect" – a hefty surge in cancer-focused biotech stocks that always accompanies the start of this meeting.
And we usually recommend an oncology stock or two ourselves.
This year's ASCO turned us on to an important new trend – one that's shaping up as the next big profit opportunity in biotech.